Arcturus Therapeutics Holdings (ARCT) Income from Continuing Operations (2018 - 2026)
Arcturus Therapeutics Holdings (ARCT) posted Income from Continuing Operations of 56613000.0 for Q1 2026, down 94.78% on a QoQ basis from 29065186.0 in Q4 2025, and down 302.2% year-over-year from 27999177.4 in Q1 2025.
Arcturus Therapeutics Holdings (ARCT) Income from Continuing Operations (2018 - 2026) Analysis & Trends
Arcturus Therapeutics Holdings' Income from Continuing Operations history runs 9 years deep, the most recent figure standing at 56613000.0 for Q1 2026.
- Quarterly Income from Continuing Operations fell 302.2% year-over-year to 56613000.0 in Q1 2026, while the trailing twelve-month figure through Mar 2026 was 108306186.0 (down 58.92% YoY) and the FY2025 annual result came in at 65769186.0, up 18.74% from the prior year.
- Income from Continuing Operations was 56613000.0 for Q1 2026 at Arcturus Therapeutics Holdings, down from 29065186.0 in the prior quarter.
- Across five years, Income from Continuing Operations topped out at 118642000.0 in Q4 2022 and bottomed at 56613000.0 in Q1 2026.
- A 5-year average of 13087305.06 and a median of 17166000.0 in 2024 frame the typical range for Income from Continuing Operations.
- Annual changes were most pronounced in 2022 — Income from Continuing Operations soared 413.74% — and 2026, when it sank 302.2%.
- Arcturus Therapeutics Holdings' Income from Continuing Operations stood at 118642000.0 in 2022, then plunged by 109.87% to 11707000.0 in 2023, then tumbled by 156.3% to 30005000.0 in 2024, then climbed by 3.13% to 29065186.0 in 2025, then slumped by 94.78% to 56613000.0 in 2026.
- Business Quant data shows ARCT's Income from Continuing Operations at 56613000.0 in Q1 2026, 29065186.0 in Q4 2025, and 13448000.0 in Q3 2025.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Income (Continuing) (Qtr) |
|---|---|---|---|---|---|
| 1 | Oculis Holding AG | 68,785.72 Bn | 68,785.72 Bn | - | -37.09 Mn |
| 2 | Nanobiotix | 1,895.57 Bn | 1,895.51 Bn | - | - |
| 3 | BeOne Medicines | 471.35 Bn | 466.56 Bn | 1.35 Bn | 227.36 Mn |
| 4 | NuCana | 279.75 Bn | 279.75 Bn | - | -3.68 Mn |
| 5 | Vertex Pharmaceuticals | 120.24 Bn | 113.00 Bn | 2.59 Bn | 1.03 Bn |
| 6 | Regeneron Pharmaceuticals | 67.80 Bn | 59.04 Bn | 3.31 Bn | 727.20 Mn |
| 7 | Belite Bio | 62.51 Bn | 62.51 Bn | - | -26.94 Mn |
| 8 | Argenx Se | 57.38 Bn | 57.38 Bn | 1.41 Bn | 362.00 Mn |
| 9 | Revolution Medicines | 37.78 Bn | 37.78 Bn | - | -453.82 Mn |
| 10 | Arcturus Therapeutics Holdings | 164.57 Mn | -46.81 Mn | - | -56.61 Mn |
Historic Data
Download Data| Date | Value |
|---|---|
| Mar 31, 2026 | -56.61 Mn |
| Dec 31, 2025 | -29.07 Mn |
| Sep 30, 2025 | -13.45 Mn |
| Jun 30, 2025 | -9.18 Mn |
| Mar 31, 2025 | -14.08 Mn |
| Dec 31, 2024 | -30.01 Mn |
| Sep 30, 2024 | -6.90 Mn |
| Jun 30, 2024 | -17.17 Mn |
| Mar 31, 2024 | -26.82 Mn |
| Dec 31, 2023 | -11.71 Mn |
| Sep 30, 2023 | -16.23 Mn |
| Jun 30, 2023 | -52.57 Mn |
| Mar 31, 2023 | 50.75 Mn |
| Dec 31, 2022 | 118.64 Mn |
| Sep 30, 2022 | -35.27 Mn |
| Jun 30, 2022 | -21.56 Mn |
| Mar 31, 2022 | -51.27 Mn |
| Dec 31, 2021 | -37.82 Mn |
| Sep 30, 2021 | -61.28 Mn |
| Jun 30, 2021 | -61.69 Mn |